Analysis of Claudin-1 and -4 as potential treatment targets in penile squamous cell carcinoma
Year: 2026
Type: article
Study design: Observational Study
Abstract: BACKGROUND: Penile carcinoma (PC) is a rare malignancy with an adverse prognosis for patients with tumors at advanced stages. Platinum-based chemotherapy still represents the standard of care but offers limited long-term survival benefit, necessitating the exploration of additional therapeutic targets. Claudin-1 and Claudin-4, key components of cellular tight junctions, play a role in the evolution and progression of various tumor types and may play a therapeutic role in PC. METHODS: In this study, we analyzed the expression and prognostic value of Claudin-1 and Claudin-4 in a multi-institutional international cohort (n = 193) of patients with PC. Tissue microarrays (TMAs) comprising representative tumor cores from the tumor center, invasive front, lymph node metastases, and normal penile tissue were used. H-scores of Claudin-1 and Claudin-4 were compared across tumor localizations, tumor stages, histologic subtypes, grades and HPV groups. Patient survival was correlated with Claudin-1 and Claudin-4 expression via Kaplan-Meier analysis. RESULTS: Claudin-1 was consistently expressed across tumor locations and was expressed in both HPV+ and HPV- tumors. Furthermore, Claudin-1 expression in FRONT samples was moderately correlated with its expression in CENTER samples. No significant differences in Claudin-1 expression were observed between different tumor stages, histologic subtypes and other clinicopathological characteristics. Moderate or strong Claudin-4 expression (H-score ≥ 100) was observed in 13.5% and 11.5% of FRONT and CENTER samples, respectively. The difference in OS between Claudin-4 CENTER expression groups was nominally significant (p = 0.024) but not after correction for multiple testing (adjusted p = 0.21). CONCLUSION: Claudin-1 and, to a lesser extent, Claudin-4 are expressed in PC and corresponding metastases, supporting further investigation of these proteins as candidate targets in local and advanced PC.
Source: Diagnostic Pathology
Institutions: Friedrich-Alexander-Universität Erlangen-Nürnberg, Universitätsklinikum Erlangen, Comprehensive Cancer Center Erlangen, Saarland University, Universitätsklinikum Wiener Neustadt, Ministry of Health of the Russian Federation, Universidade do Porto, IPO Porto, Westpfalz Klinikum, Sankt-Antonius-Hospital Eschweiler, Universitätsklinikum des Saarlandes
Language: English
Topic: Genital Health and Disease
Subfield: Surgery
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $2,990
Funder: Universitätsklinikum Erlangen
OpenAlex ID: W7236499524
